HOME >> MEDICINE >> NEWS
Penn State to host national symposium on fertility decline in developed countries

In most highly developed countries more and more women are choosing to have fewer or no children, to delay childbearing (often until the chances of having a viable pregnancy are greatly reduced), and to have children outside of marriage. Overall, adults appear to be less interested in investing in children now than in the past.

Family scholars from across the nation will converge on Penn State on October 9-10 for the Penn State Annual National Family Symposium to examine the reasons for depressed fertility and the factors people consider when deciding whether or not to have children and when to have them.

The symposium will be held at the Nittany Lion Inn on Penn State's University Park campus. This year it is titled "Creating the Next Generation: Social, Economic, and Psychological Processes Underlying Fertility in Developed Countries." Symposium speakers and discussants will consider what led to these contemporary fertility patterns and what they portend for union formation, the well-being of children and adults, and the integrity of society as a whole, now and in the future.

The symposium, organized by Alan Booth, distinguished professor of sociology, human development and demography, and Ann C. Crouter, professor of human development and family studies, both of Penn State, will be structured around four important issues that underlie these changes.

S. Philip Morgan, Duke University, will explore contemporary patterns and trends in U.S. fertility, focusing on where we have come from and where we may be headed. Jennifer Barber and William Axinn, University of Michigan, will examine how social and cultural values and attitudes shape fertility patterns in the developed world. Elizabeth Thomson, University of Wisconsin, will analyze the factors explaining how fertility has become uncoupled from marriage. Christine Bachrach, National Institute of Child Health and Human Development; Lynn White; University of Nebraska; and Daniel Lichter, Oh
'"/>

Contact: William Harnish
William@pop.psu.edu
Penn State
18-Aug-2003


Page: 1 2

Related medicine news :

1. International breast cancer prevention study launches in the United States and Canada
2. Statement on the findings of the Womens Health Study
3. States find alternate routes to health coverage
4. State policies decrease youth smoking, drinking and sex
5. State of the heart news conference
6. CDC: Update on current influenza season and vaccine supply in the United States
7. Immigrants, beware: Living in the United States is fattening
8. NIH panel issues State-of-the-Science statement on end-of-life care
9. Landmark survey reveals asthma in children remains significantly out of control in the United States
10. NIH convenes State-of-the-Sceince Conference on Improving End-of-Life Care
11. The Gerontological Society of America confers 2004 M. Powell Lawton Award to Penn States Zarit

Post Your Comments:
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... some of the changes brought about by the disorder ... New research has found that people with diabetes who ... risk of having a severe low blood sugar (hypoglycemia) ... people with diabetes who aren,t depressed. "Depression ...
(Date:5/21/2013)... long been known for their health benefits, and ... like anti-cancer drugs are delivered to specific tumor ... how to create nanoparticles using natural lipids derived ... them as drug delivery vehicles. UofL scientists Huang-Ge ... team today (May 21, 2013), published their findings ...
(Date:5/21/2013)... Schaumburg, IL (PRWEB) May 21, 2013 ... administration for large, medium, and small organizations, will be ... featuring an experts team from Findley Davies. The presentation ... is up-to-date and in compliance with new Health Care ... ideas to engage employees. , “Benefit Express regularly ...
(Date:5/21/2013)... May 21, 2013 Dr. Francine Kaufman , ... she used with her patients in the 1980s: It weighed several ... For the most part, it could only be used in the ... years since then, and the advantages are greater as well. The ... outside of the body, often on a belt or a pocket. ...
(Date:5/21/2013)... 21, 2013 A plastic surgery ... for plastic surgery SEO services following an Internet ... to name the “Best Plastic Surgery SEO Services”. ... outcome was predictable. Well-known in the plastic surgery ... patients than any other selection based on superior ...
Breaking Medicine News(10 mins):Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Benefit Express to Host Workplace Wellness Webinar 2Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 2Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 3Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 4Health News:JD Media Surge's CosmeticSurgeonsOnline.com Voted #1 Source for Plastic Surgery SEO 2
(Date:5/21/2013)... WESTBURY, N.Y. , May 21, 2013  Vasomedical, Inc. ... specializing in the design, manufacture and sale of medical devices ... today that Dr. Jun Ma , President ... Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 ... Grand Hyatt Hotel. The Company,s presentation is ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Technologies for Optical Coherence Tomography (OCT) ... STUDY OBJECTIVES   ... study is to offer synopsis of the ...
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
Cached News: